Anteris Technologies Reports positive data from first-in-human heart valve trial
- Meditech specialist Anteris Technologies (ARV) reports “excellent” results from the first-in-human trial of its DurAVR replacement heart valve
- The company has surgically installed the valve in five patients of a 10-patient trial, with positive results recorded at the 30-day follow up point
- There were no adverse events in any patients, with some key measures of heart valve function improved compared to other replacement heart valves
- Anteris says importantly, exercise tolerance in patients was greatly improved compared to other observed studies of replacement valves
- Shares in AnterisTechnologies are slightly lower this afternoon, down 0.59 per cent to trade at $16.90
